# ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

> **NCT03698552** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 37 (actual)

## Conditions studied

- Blasts 5 Percent or More of Bone Marrow Nucleated Cells
- CD22 Positive
- Philadelphia Chromosome Positive
- Recurrent B Acute Lymphoblastic Leukemia
- Refractory B Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** ADCT-602

## Key facts

- **NCT ID:** NCT03698552
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-24
- **Primary completion:** 2025-11-06
- **Final completion:** 2025-11-06
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** \<75% participation
- **Last updated:** 2025-12-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03698552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03698552, "ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03698552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*